The market for Venous Thromboembolism (VTE) Treatment is expected to reach US$ XX Bn in 2022.
According to Cleveland Clinic, venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects hospitalized and non-hospitalized patients, recurs frequently, is often overlooked, and results in long-term complications, including chronic thromboembolic pulmonary hypertension (CTPH) and post-thrombotic syndrome (PTS). An inclusive scientific review by the WTD steering committee revealed that 10 million cases of VTE occur annually – across low, middle, and high-income countries. In addition, up to 60% of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital death. The venous thromboembolism treatment market can be segmented into diseases such as deep venous thrombosis (DVT) and pulmonary embolism (PE). The venous thromboembolism treatment market is segmented based on drugs such as heparin, apixaban, dabigatran, rivaroxaban, edoxaban, and warfarin. The therapy market for VTE treatment comprises compression therapy and thrombolytic therapy.
The key drivers assisting the overall market growth of venous thromboembolism treatment are increasing prevalence and incidence rate of venous thromboembolism, and high awareness related to existing treatments for venous thromboembolism are driving the global venous thromboembolism treatment market. In addition, factors such as stringent regulatory approvals and challenges in adapting newer drugs and therapies in the market are restraining the growth of this market. North America is the leading regional market for venous thromboembolism treatments. Europe trails it due to a large population suffering from venous thromboembolic in these regions. The key factors driving North America and Europe’s venous thromboembolism market are high healthcare expenditure, developed healthcare infrastructure, and high awareness of the disease and available treatments.
Abbott Laboratories, Merck & Co., Sanofi S.A., Dupont Pharm Co, Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Wockhardt Ltd, Bayer AG, Bristol-Myers Squibb Company, 3M Health Care, ArjoHuntleigh, BSN medical, Medtronic plc, Bio Compression Systems, Inc., and Pfizer Inc. and others.
The market for Venous Thromboembolism (VTE) Treatment is expected to reach US$ XX Bn in 2022.
The Venous Thromboembolism (VTE) Treatment Market is expected to see significant CAGR growth over the coming years, at XX %.
The report is forecasted from 2016-2022.
The base year of this report is 2021.